Nymox Pharmaceutical Corp. announce that the plans cancer treatment candidate after to the result in the laboratory rodents testing, the shares pushing in higher to this afternoon trading, The company stock $1.18, or 27.5 percent, to reach $5.47. Earlier, shares reached a two-year high of $7.07.
Preclinical studies to the treatment's potential impact on humans and companies. In such studies in still development of the companies. A compound could show fantastic results in laboratory mice and rats, but then fail miserably in humans.
No comments:
Post a Comment